CN107937440A - 猴腺病毒(大猩猩)或腺病毒载体及其使用方法 - Google Patents

猴腺病毒(大猩猩)或腺病毒载体及其使用方法 Download PDF

Info

Publication number
CN107937440A
CN107937440A CN201711203173.3A CN201711203173A CN107937440A CN 107937440 A CN107937440 A CN 107937440A CN 201711203173 A CN201711203173 A CN 201711203173A CN 107937440 A CN107937440 A CN 107937440A
Authority
CN
China
Prior art keywords
acid sequence
seq
adenovirus
amino acid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711203173.3A
Other languages
English (en)
Chinese (zh)
Inventor
邓肯·麦克维伊
道格拉斯·E·布拉夫
詹森·G·D·加尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of CN107937440A publication Critical patent/CN107937440A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10333—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201711203173.3A 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法 Pending CN107937440A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543652P 2011-10-05 2011-10-05
US61/543,652 2011-10-05
CN201280059668.2A CN103974970B (zh) 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280059668.2A Division CN103974970B (zh) 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法

Publications (1)

Publication Number Publication Date
CN107937440A true CN107937440A (zh) 2018-04-20

Family

ID=47045180

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201711203173.3A Pending CN107937440A (zh) 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
CN201280059668.2A Active CN103974970B (zh) 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280059668.2A Active CN103974970B (zh) 2011-10-05 2012-10-05 猴腺病毒(大猩猩)或腺病毒载体及其使用方法

Country Status (9)

Country Link
US (3) US9629906B2 (enExample)
EP (1) EP2764013B1 (enExample)
JP (2) JP6757120B2 (enExample)
CN (2) CN107937440A (enExample)
BR (1) BR112014008249B1 (enExample)
CA (1) CA2850627C (enExample)
HK (1) HK1252010A1 (enExample)
IN (1) IN2014DN03061A (enExample)
WO (1) WO2013052811A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US9617560B2 (en) * 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US9580476B2 (en) * 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
IN2014DN03061A (enExample) * 2011-10-05 2015-05-15 Genvec Inc
HK1210475A1 (en) * 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
KR20220163505A (ko) 2016-02-23 2022-12-09 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
MX2019002178A (es) 2016-08-23 2019-09-18 Glaxosmithkline Biologicals Sa Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US11155832B2 (en) 2016-09-30 2021-10-26 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into T cells
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN110036020A (zh) 2016-12-09 2019-07-19 葛兰素史密丝克莱恩生物有限公司 具有狂犬病病毒抗原的黑猩猩腺病毒构建体
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
GB201701239D0 (en) 2017-01-25 2017-03-08 Glaxosmithkline Biologicals Sa Novel formulation
US11649467B2 (en) 2017-07-21 2023-05-16 Glaxosmithkline Biologicals Sa Chikungunya virus antigen constructs
KR20250136930A (ko) 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
JP2021514666A (ja) 2018-03-06 2021-06-17 プレシゲン，インコーポレイテッド Ｂ型肝炎ワクチンおよびその使用
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
KR20220076510A (ko) 2019-10-08 2022-06-08 트러스티스 오브 보스톤 칼리지 다수의 서로 다른 비천연 아미노산을 함유하는 단백질 및 이러한 단백질의 제조 및 사용 방법
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016344A1 (fr) * 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
CN1578678A (zh) * 2001-11-21 2005-02-09 宾夕法尼亚州立大学托管会 猿猴腺病毒的核酸和氨基酸序列,含有它们的载体以及用法
CN101014613A (zh) * 2004-01-23 2007-08-08 P·安杰莱蒂分子生物学研究所 黑猩猩腺病毒疫苗载运体
CN101072879A (zh) * 2004-10-13 2007-11-14 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
WO1997026911A1 (en) 1996-01-29 1997-07-31 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU2001234981A1 (en) 2000-02-09 2001-08-20 Genvec, Inc. Adenoviral capsid containing chimeric protein ix
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US20040136963A1 (en) 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
WO2003020879A2 (en) 2001-07-23 2003-03-13 Genvec, Inc. Cells and methods for propagating adenoviral vectors
WO2003022311A1 (en) 2001-09-13 2003-03-20 Genvec, Inc. Adenoviral vector and related system and methods of making and use
WO2005075506A1 (en) 2004-01-09 2005-08-18 The Scripps Research Institute Identification of endogenous trimerization domains in the adenovirus fiber protein that allow detargeting and retargeting of viral vectors
WO2006065827A2 (en) 2004-12-13 2006-06-22 Canji, Inc. Cell lines for production of replication-defective adenovirus
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
AU2007275047A1 (en) 2006-07-20 2008-01-24 University Of Washington Compositions and methods for vaccinating against HSV-2
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
AU2010278797A1 (en) 2009-07-31 2012-03-15 Paxvax, Inc. Adenoviral-based vectors
AU2010314842A1 (en) * 2009-11-09 2012-05-31 Genvec, Inc. Methods of propagating monkey adenoviral vectors
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
WO2012021730A2 (en) * 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
US9580476B2 (en) * 2011-10-05 2017-02-28 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
US9617560B2 (en) * 2011-10-05 2017-04-11 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
US9233153B2 (en) * 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
IN2014DN03061A (enExample) * 2011-10-05 2015-05-15 Genvec Inc
WO2013116591A1 (en) * 2012-02-02 2013-08-08 Genvec, Inc. Adenoviral vector-based malaria vaccine
HK1210475A1 (en) 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016344A1 (fr) * 1999-08-27 2001-03-08 Transgene S.A. Fibre adenovirale modifiee et utilisations
CN1578678A (zh) * 2001-11-21 2005-02-09 宾夕法尼亚州立大学托管会 猿猴腺病毒的核酸和氨基酸序列,含有它们的载体以及用法
CN101014613A (zh) * 2004-01-23 2007-08-08 P·安杰莱蒂分子生物学研究所 黑猩猩腺病毒疫苗载运体
CN101072879A (zh) * 2004-10-13 2007-11-14 克鲁塞尔荷兰公司 改良的腺病毒载体及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROY,S.等: "Simian adenovirus 45, complete genome", 《GENEBANK DATABASE》 *
SOUMITRA ROY等: "Isolation and Characterization of Adenoviruses Persistently Shed from the Gastrointestinal Tract of Non-Human Primates", 《PLOS PATHGENS》 *
张荣建等: "猴腺病毒研究进展", 《中国比较医学杂志》 *
梅兴国: "《微载体药物递送系统》", 30 November 2009, 华中科技大学出版社 *

Also Published As

Publication number Publication date
JP6757120B2 (ja) 2020-09-16
US10272162B2 (en) 2019-04-30
IN2014DN03061A (enExample) 2015-05-15
WO2013052811A2 (en) 2013-04-11
EP2764013A2 (en) 2014-08-13
US20140248308A1 (en) 2014-09-04
WO2013052811A3 (en) 2013-06-20
EP2764013B1 (en) 2022-01-26
BR112014008249A2 (pt) 2017-04-18
US9629906B2 (en) 2017-04-25
CN103974970A (zh) 2014-08-06
JP6970060B2 (ja) 2021-11-24
JP2018198603A (ja) 2018-12-20
HK1252010A1 (zh) 2019-05-10
US10792376B2 (en) 2020-10-06
CA2850627C (en) 2024-05-21
BR112014008249B1 (pt) 2022-03-15
JP2014530605A (ja) 2014-11-20
CA2850627A1 (en) 2013-04-11
US20170246318A1 (en) 2017-08-31
CN103974970B (zh) 2018-01-02
US20190269794A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
HK1252010A1 (zh) 猴腺病毒(大猩猩)或腺病毒载体及其使用方法
AU2022203504B2 (en) Oncolytic tumor viruses and methods of use
AU2019271972B2 (en) Adenovirus polynucleotides and polypeptides
KR101761425B1 (ko) 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
KR102205908B1 (ko) 아데노바이러스 벡터
KR101761691B1 (ko) 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
AU2011332025B2 (en) Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
KR102582561B1 (ko) 비인간 대형 유인원 아데노바이러스 핵산-서열 및 아미노산-서열, 이를 포함하는 벡터 및 그의 용도
CN107574154A (zh) 猴(大猩猩)腺病毒或腺病毒载体及其使用方法
AU2017223589B2 (en) Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CN108135991A (zh) 新型腺病毒
CN116940589A (zh) 重组sars-cov-2疫苗
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
CN112011570B (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
NL2023464B1 (en) Oncolytic Non-human adenoviruses and uses thereof
DK2391638T3 (en) Abeadenovirus nucleic acid and amino acid sequences, vectors containing them, and uses thereof.
CZ413199A3 (cs) Způsob výroby adenovirových vektorů nepatřících do skupiny C

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252010

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180420

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1252010

Country of ref document: HK